| Literature DB >> 34290303 |
Anna Polewczyk1,2, Wojciech Jacheć3, Luca Segreti4, Maria Grazia Bongiorni4, Andrzej Kutarski5.
Abstract
The specific role of the various pathogens causing cardiac implantable electronic devices-(CIEDs)-related infections requires further understanding. The data of 1241 patients undergoing transvenous lead extraction because of lead-related infective endocarditis (LRIE-773 patients) and pocket infection (PI-468 patients) in two high-volume centers were analyzed. Clinical course and long-term prognosis according to the pathogen were assessed. Blood and generator pocket cultures were most often positive for methicillin-sensitive Staphylococcus aureus (MSSA: 22.19% and 18.13% respectively), methicillin-sensitive Staphylococcus epidermidis (MSSE: 17.39% and 15.63%) and other staphylococci (11.59% and 6.46%). The worst long-term prognosis both in LRIE and PI subgroup was in patients with infection caused by Gram-positive microorganisms, other than staphylococci. The most common pathogens causing CIED infection are MSSA and MSSE, however, the role of other Gram-positive bacteria and Gram-negative organisms is also important. Comparable, high mortality in patients with LRIE and PI requires further studies.Entities:
Year: 2021 PMID: 34290303 PMCID: PMC8295258 DOI: 10.1038/s41598-021-94168-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1LRIE subgroup—list of pathogens.
Figure 2PI subgroup—list of pathogens.
Demographic and clinical data of patients admitted for lead extraction due to infection.
| All group (patients with CIED related infections) | LRIE | PI | ||
|---|---|---|---|---|
Male n (%) | 908 (73.00) n = 1241 | 559 (72.32) n = 773 | 349 (74.15) n = 468 | |
Female n (%) | 333 (26.99) n = 1241 | 214 (27.68) n = 773 | 119 (25.85) n = 468 | |
Mean age (first implantation) mean ± sd | 60.811 ± 14.966 n = 1241 | 60.435 ± 14.693 n = 773 | 61.365 ± 15.278 n = 468 | 0.107 |
Mean age (TLE), mean, SD Mean ± SD | 67.947 ± 13.662 n = 1241 | 67.802 ± 13.378 n = 773 | 68.130 ± 14.053 n = 468 | 0.380 |
BMI [kg/m2] Mean ± SD | 27.105 ± 4.028 n = 1199 | 27.205 ± 4.252 n = 710 | 26.917 ± 3.583 n = 389 | 0.250 |
LVEF [%] Mean ± SD | 48.114 ± 14.363 n = 1190 | 48.107 ± 14.226 n = 750 | 48.050 ± 14.249 n = 440 | |
NYHA class Mean ± SD | 1.740 ± 3.143 n = 1235 | 1.699 ± 0.774 n = 770 | 1.574 ± 0.707 n = 465 | 0.008 |
Presence of valvular implants n (%) | 75 (6.04) n = 1241 | 46 (5.95) n = 773 | 29 (6.20) n = 468 | |
Prior sternotomy n (%) | 194 (15.84) n = 1225 | 122 (15.80) n = 759 | 72 (16.14) n = 466 | |
Arterial hypertension n (%) | 774 (62.37) 1241 | 486 (62.87) 773 | 288 (61.54) 468 | |
Diabetes n (%) | 270 (22.00) n = 1227 | 182 (23.88) n = 762 | 88 (18.92) n = 465 | |
History of CKD or eGFR < 60 ml/min/1.73 m2 n (%) | 62 (5.45) n = 1137 | 49 (6.77) n = 724 | 13 (3.15) n = 413 | |
Creatinine concentrations [mg/dl] Mean ± SD | 1.264 ± 0.831 n = 1137 | 1.308 ± 0.865 n = 724 | 1.186 ± 0.762 n = 413 | |
Permanent atrial fibrillation n (%) | 291 (23.68) n = 1229 | 166 (21.76) n = 763 | 125 (26.82) n = 466 | |
Permanent anticoagulation n (%) | 391 (32.58) n = 1200 | 248 (32.98) n = 752 | 144 (32.14) n = 448 | |
Permanent antiplatelet therapy n (%) | 476 (39.67) n = 1200 | 304 (40.43) n = 752 | 172 (38.39) n = 448 | |
Device without ICD lead n (%) | 794 (63.98) n = 1241 | 499 (64.55) n = 773 | 295 (63.03) n = 468 | |
Device with ICD lead n (%) | 447 (36.02) 1241 | 274 (35.45) 773 | 173 (36.97) 468 | |
| Dwelling time for oldest lead [months], Mean ± SD | 86.525 ± 69.373 n = 1241 | 89.187 ± 69.686 n = 773 | 82.011 ± 68.717 n = 468 | |
| Number of CIED-related operative procedures before TLE (upgrading, pocket revision) Mean ± SD | 0.838 ± 1.197 n = 1241 | 0.816 ± 1.266 n = 773 | 0.868 ± 1.065 n = 468 | |
| Number of all operative procedures before TLE (implantations, reimplantation, upgrading, pocket revision) Mean ± SD | 2.413 ± 1.561 n = 1241 | 2.425 ± 1.654 n = 773 | 2.385 ± 1.389 n = 468 | |
Presence of intracardiac lead abrasion n (%) | 213 (26.93) n = 791 | 163 (29.37) n = 555 | 50 (21.19) (n = 236) | |
Number of leads in system Mean ± SD | 1.956 ± 0.673 n = 1241 | 1.948 ± 0.670 n = 773 | 1.970 ± 0.679 n = 468 | |
Number of patients with abandoned leads n (%) | 246 (19.82) N = 1241 | 162 (20.95) N = 773 | 84 (17.95) N = 468 | |
| Mean number of abandoned leads in patients Mean ± SD | 0.255 ± 0.627 n = 1241 | 0.267 ± 0.613 n = 773 | 0.235 ± 0.639 n = 468 | |
Total number of leads in patient Mean ± SD | 2.211 ± 0.859 n = 1241 | 2.214 ± 0.873 n = 773 | 2.205 ± 0.820 n = 468 | |
Vegetations presence n (%) | 522 (42.06) n = 1241 | 522 (67.53) n = 773 | 0 (0.00) n = 468 | |
Presence of large vegetation > 2 cm2 n (%) | 146 (11.76) n = 1241 | 146 (18.89) n = 773 | 0 (0.00) n = 468 | |
Technical problems or complications during TLE Mean ± SD | 0.152 ± 0.359 n = 1241 | 0.145 ± 0.352 n = 773 | 0.163 ± 0.370 n = 468 | |
| Number of patients with technical problems or complications during TLE n(%) | 188 (15.15) n = 1241 | 112 (14.45) n = 773 | 76 (16.24) n = 468 | |
Procedure duration time [min] Mean ± SD | 105.280 ± 50.684 n = 1241 | 107.854 ± 50.017 n = 766 | 100.869 ± 44.346 n = 464 | |
Radiological success n (%) | 1172 (94.44) n = 1241 | 732 (94.70) n = 773 | 441 (94.23) n = 468 | |
Clinical success n (%) | 1199 (96.62) n = 1241 | 749 (96.90) n = 773 | 450 (96.15) n = 468 | |
Major complications n (%) | 18 (1.45) n = 1241 | 14 (1.81) n = 773 | 4 (0.85) n = 468 | |
Minor complications n (%) | 69 (5.56) n = 1241 | 48 (6.21) n = 773 | 21 (4.49) n = 468 | |
Periprocedural deaths n (%) | 7 (5.46) n = 1241 | 6 (0.78) n = 773 | 1 (0.21) n = 468 | |
Follow-up [days] Mean ± SD | 1589,0 ± 1041,2 n = 1071 | 1543,9 ± 1042,1 n = 696 | 1672,7 ± 1035,7 n = 375 | |
Death during follow-up n (%) | 369 (34.45) n = 1071) | 254 (36.49) n = 696) | 115 (30.67) n = 375 | |
AF, atrial fibrillation; CIED, cardiac implantable electronic devices; CKD, chronic kidney disease; eGFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; LRIE, lead related infective endocarditis, LVEF, left ventricular ejection fraction, PI, pocket infections, SD, standard deviation, TLE, transvenous lead extraction.
Figure 3Kaplan–Meier probability of survival depending on indications for transvenous lead extraction procedure.
Figure 4Probability of survival in patients with LRIE depending on pathogen type.
Risk factors for deaths after TLE in LRIE patients.
| n = 641 (complete data) | HR | 95% CI | |
|---|---|---|---|
| Age of patients during TLE (1 year) | 1.031 | 1.019–1.044 | < 0.001 |
| NYHA (1 class) | 1.500 | 1.250–1.800 | < 0.001 |
| Lower LVEF (1%p) | 1.017 | 1.007–1.027 | < 0.001 |
| Permanent atrial fibrillation | 1.389 | 1.050–1.837 | 0.021 |
| Lower haemoglobin concentration (1 g/dl) | 1.075 | 1.005–1.149 | 0.035 |
| Creatinine (1 mg %) | 1.277 | 1.134–1.439 | < 0.001 |
| Pathogen other than MSSE | 1.876 | 1.256–2.703 | < 0.001 |
Results of multivariable stepwise Cox regression model.
LRIE, lead related infection endocarditis, LVEF, left ventricular ejection fraction, MSSE, methicillin sensitive S. epidermidis; NYHA, New York Heart Association (class), TLE, transvenous lead extraction.
Figure 5Probability of survival in patients with PI depending on pathogen type.
Risk factors for deaths after TLE in PI patients.
| n = 325 (complete data) | HR | 95% CI | |
|---|---|---|---|
| Age of patients during TLE (1 year) | 1.023 | 1.003–1.043 | 0.022 |
| NYHA (1 class) | 1.705 | 1.251–2.324 | < 0.001 |
| Lower LVEF (1%p) | 1.018 | 1.003–1.034 | 0.018 |
| Arterial hypertension | 1.671 | 1.019–2.738 | 0.042 |
| Diabetes | 1.809 | 1.136–2.879 | 0.012 |
| Lower haemoglobin concentration (1 g/dl) | 1.311 | 1.166–1.473 | < 0.001 |
| Creatinine (1 mg %) | 1.144 | 0.992–1.319 | 0.065 |
| 15.630 | 3.451–70.798 | < 0.001 |
Results of multivariable stepwise Cox regression model.
LVEF—Left ventricular ejection fraction; NYHA—New York Heart Association (class); PI—pocket infection; TLE—transvenous lead extraction.